Who are "Metronidazole" and "Lactobacillus"'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "Probiotics" and "Metronidazole".

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metronidazole-and-lactobacillus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

"Metronidazole" and "Lactobacillus" — Competitive Intelligence Brief

"Metronidazole" and "Lactobacillus" ("Metronidazole" and "Lactobacillus") competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic + Probiotic combination. Area: Infectious Disease / Gastroenterology.

marketed Antibiotic + Probiotic combination Infectious Disease / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

"Metronidazole" and "Lactobacillus" ("Metronidazole" and "Lactobacillus") — Peking University Shenzhen Hospital. Metronidazole kills anaerobic bacteria and protozoa by damaging their DNA, while Lactobacillus restores beneficial gut flora to prevent dysbiosis-related complications.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
"Metronidazole" and "Lactobacillus" TARGET	"Metronidazole" and "Lactobacillus"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination
"Probiotics" and "Metronidazole"	"Probiotics" and "Metronidazole"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic + Probiotic combination class)

Peking University Shenzhen Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). "Metronidazole" and "Lactobacillus" — Competitive Intelligence Brief. https://druglandscape.com/ci/metronidazole-and-lactobacillus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab